These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 9322842)

  • 41. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy.
    Oshiro S; Tsugu H; Komatsu F; Abe H; Onishi H; Ohmura T; Iwaasa M; Sakamoto S; Fukushima T
    Anticancer Res; 2007; 27(6A):3757-63. PubMed ID: 17970039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values.
    Senft C; Hattingen E; Pilatus U; Franz K; Schänzer A; Lanfermann H; Seifert V; Gasser T
    Neurosurgery; 2009 Nov; 65(5):908-13; discussion 913. PubMed ID: 19834403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Independent component analysis to proton spectroscopic imaging data of human brain tumours.
    Pulkkinen J; Häkkinen AM; Lundbom N; Paetau A; Kauppinen RA; Hiltunen Y
    Eur J Radiol; 2005 Nov; 56(2):160-4. PubMed ID: 16233889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study.
    Appenzeller S; Li LM; Costallat LT; Cendes F
    Brain; 2005 Dec; 128(Pt 12):2933-40. PubMed ID: 16195241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutoff value of choline concentration reliably reveals high-grade brain tumors among other contrast-enhancing brain lesions.
    Porto L; Hattingen E; Stuecher A; Herminghaus S; Lanfermann H; Ulrich Pilatus UP
    J Neurol Surg A Cent Eur Neurosurg; 2012 May; 73(3):147-52. PubMed ID: 22190143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors.
    Tzika AA; Astrakas LG; Zarifi MK; Zurakowski D; Poussaint TY; Goumnerova L; Tarbell NJ; Black PM
    Cancer; 2004 Mar; 100(6):1246-56. PubMed ID: 15022293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
    Guillevin R; Menuel C; Taillibert S; Capelle L; Costalat R; Abud L; Habas C; De Marco G; Hoang-Xuan K; Chiras J; Vallée JN
    Br J Cancer; 2011 Jun; 104(12):1854-61. PubMed ID: 21610707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression.
    Imani F; Boada FE; Lieberman FS; Davis DK; Deeb EL; Mountz JM
    J Neuroimaging; 2012 Apr; 22(2):184-90. PubMed ID: 21155917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton magnetic resonance spectroscopy of pediatric brain tumors.
    Sutton LN; Wang Z; Gusnard D; Lange B; Perilongo G; Bogdan AR; Detre JA; Rorke L; Zimmerman RA
    Neurosurgery; 1992 Aug; 31(2):195-202. PubMed ID: 1513425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging.
    Ziegler A; von Kienlin M; Décorps M; Rémy C
    Cancer Res; 2001 Jul; 61(14):5595-600. PubMed ID: 11454713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The diagnostic challenge of lack of choline level elevation on 1H-MR spectroscopy in grade II-III gliomas.
    Bobek-Billewicz B; Heinze S; Majchrzak K; Mazgaj P; Hebda A
    Folia Neuropathol; 2024; 62(1):13-20. PubMed ID: 38741433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.
    Balmaceda C; Critchell D; Mao X; Cheung K; Pannullo S; DeLaPaz RL; Shungu DC
    J Neurooncol; 2006 Jan; 76(2):185-91. PubMed ID: 16151595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy.
    Palumbo B; Lupattelli M; Pelliccioli GP; Chiarini P; Moschini TO; Palumbo I; Siepi D; Buoncristiani P; Nardi M; Giovenali P; Palumbo R
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):88-93. PubMed ID: 16557208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proton magnetic resonance spectroscopy-guided biopsy for cerebral glial tumors.
    Chen CY; Lirng JF; Chan WP; Fang CL
    J Formos Med Assoc; 2004 Jun; 103(6):448-58. PubMed ID: 15278190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic accuracy of proton magnetic resonance spectroscopy and perfusion-weighted imaging in brain gliomas follow-up: a single institutional experience.
    Anselmi M; Catalucci A; Felli V; Vellucci V; Di Sibio A; Gravina GL; Di Staso M; Di Cesare E; Masciocchi C
    Neuroradiol J; 2017 Jun; 30(3):240-252. PubMed ID: 28627984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study.
    Plotkin M; Eisenacher J; Bruhn H; Wurm R; Michel R; Stockhammer F; Feussner A; Dudeck O; Wust P; Felix R; Amthauer H
    J Neurooncol; 2004 Oct; 70(1):49-58. PubMed ID: 15527107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular and metabolic pattern classification for detection of brain glioma progression.
    Imani F; Boada FE; Lieberman FS; Davis DK; Mountz JM
    Eur J Radiol; 2014 Feb; 83(2):e100-5. PubMed ID: 24321226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions].
    Ando K; Ishikura R; Nagami Y; Morikawa T; Takada Y; Ikeda J; Nakao N; Matsumoto T; Arita N
    Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Mar; 64(3):121-6. PubMed ID: 15148787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma.
    Guo J; Higashi K; Yokota H; Nagao Y; Ueda Y; Kodama Y; Oguchi M; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2004 Aug; 45(8):1334-9. PubMed ID: 15299058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.
    Stadlbauer A; Moser E; Gruber S; Buslei R; Nimsky C; Fahlbusch R; Ganslandt O
    Neuroimage; 2004 Oct; 23(2):454-61. PubMed ID: 15488395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.